CD8A and breast carcinoma: These findings suggest that BRRIAR can promote pro-inflammatory cytokine production during an antigen-specific (HCMV) immune response and may potentiate CD8 + T cell and NK cell-mediated tumor cell killing in ER + breast cancer.